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Background—Prostate cancer (PCa) molecular subtypes have been defined by essentially
mutually exclusive events, including ETS gene fusions (most commonly involving ERG) and
SPINK1 over-expression. Clinical assessment may aid in disease stratification, complementing
available prognostic tests.
Objective—To determine the analytical validity and clinicopatholgical associations of
microarray-based molecular subtyping.
Design, Setting and Participants—We analyzed Affymetrix GeneChip expression profiles
for 1,577 patients from eight radical prostatectomy (RP) cohorts, including 1,351 cases assessed
using the Decipher prognostic assay (performed in a CLIA-certified laboratory). A microarraybased (m-) random forest ERG classification model was trained and validated. Outlier expression
analysis was used to predict other mutually exclusive non-ERG ETS gene rearrangements (ETS+)
or SPINK1 over-expression (SPINK1+).
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Outcome Measurements—Associations with clinical features and outcomes by multivariable
logistic regression analysis and receiver operating curves.

Author Manuscript

Results and Limitations—The m-ERG classifier showed 95% accuracy in an independent
validation subset (n=155 samples). Across cohorts, 45%, 9%, 8% and 38% of PCa were classified
as m-ERG+, m-ETS+, m-SPINK1+, and triple negative (m-ERG−/m-ETS−/m-SPINK1−),
respectively. Gene expression profiling supports three underlying molecularly defined groups (mERG+, m-ETS+ and m-SPINK1+/triple negative). On multivariable analysis, m-ERG+ tumors
were associated with lower preoperative serum PSA and Gleason scores, but enriched for
extraprostatic extension (p<0.001). m-ETS+ tumors were associated with seminal vesicle invasion
(p=0.01), while m-SPINK1+/triple negative tumors had higher Gleason scores and were more
frequent in Black/African American patients (p<0.001). Clinical outcomes were not significantly
different between subtypes.
Conclusions—A clinically available prognostic test (Decipher) can also assess PCa molecular
subtypes, obviating the need for additional testing. Clinicopathological differences were found
among subtypes based on global expression patterns.
Keywords
Prostate cancer; ERG; ETS; SPINK1; microarray; prognosis

INTRODUCTION

Author Manuscript

Prostate cancer (PCa) is clinically and molecularly heterogeneous. PCa genome and
transcriptome characterization has identified molecular subtypes defined by essentially
mutually exclusive genetic/transcriptomic events [1]. For example, approximately 50% of
PCa foci from PSA-screened Caucasian cohorts harbor rearrangements between the 5′
untranslated region of androgen responsive genes (most commonly TMPRSS2) and members
of the ETS transcription factor family [2,3]; fusions involving the ETS gene ERG are the
most common (referred to as ERG+ (comprising ~90% of all ETS fusions), while mutually
exclusive gene fusions involving non-ERG ETS genes, including ETV1, ETV4, ETV5 and
FLI1, are infrequent (referred to as ERG−/ETS+ or ETS+; collectively comprising ~10% of
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all ETS fusions)[4]. Given the rarity of ETS+ PCa, it is unclear whether they are molecularly
and clinicopathologically similar to ERG+ tumors. Approximately 10% of PCa, which are
nearly exclusively negative for ERG or other ETS gene fusions (ETS−), harbor marked
SPINK1 over-expression, consistent with a unique molecular subtype (SPINK1+)[3,5].
Although we and others have validated antibodies (against ERG and SPINK1) and
fluorescence in situ hybridization (FISH) or RNA in situ hybridization (RISH) assays
(against ETV1, ETV4, and ETV5)[4,6,7], routine comprehensive subtyping remains
challenging and is cost prohibitive given the lack of current clinical indications.

Author Manuscript
Author Manuscript

High-throughput PCa transcriptome characterization has identified prognostic biomarkers,
which have been translated to clinically available multi-gene prognostic tests compatible
with routine formalin fixed paraffin embedded (FFPE) clinical biopsy or radical
prostatectomy (RP) specimens[8–11]. Such tests must account for disease multifocality, as
most men with PCa actually harbor multiple, genetically independent tumor clones that may
have variable morphology (including Gleason score) and molecular alterations [12]. For
example, 40-70% of RP samples harbor PCa foci with divergent TMPRSS2:ERG gene
fusion status in distinct tumor foci, consistent with multiclonality [13–15]. Conflicting
reports on associations of PCa molecular subtype defining lesions—such as TMPRSS2:ERG
fusions and SPINK1 over-expression—with prognosis have been reported. Prognostic
associations are confounded by cohort differences (i.e. PSA screened vs. unscreened, biopsy
vs transurethral resection (TURP) detected, treatment modality and definition of “poor”
outcome) as well as detection methodologies[16,17]. Nevertheless, inclusion of molecular
subtyping in clinically available prognostic tests may provide additional information beyond
routine prognosis in the post-RP setting, including assessment of multiclonality/
multifocality [18–20] and predictive applications given clinical trials incorporating ETS
status (NCT01576172). Additionally, it is unclear if prognostic signatures perform equally
in different molecular PCa subtypes.
The goal of this study was to determine if PCa molecular subtyping could be performed
from the “extra” data generated by a clinically available prognostic assay (Decipher), which
utilizes genome-wide microarray expression profiling from formalin fixed paraffin
embedded (FFPE) tissues to determine a prognostic score using the expression of 22 genes
[9]. Hence, here we developed and validated computational tools for molecular subtyping
using Decipher generated microarray expression data. We then determined clinicopathologic
and prognostic associations from these microarray derived subtypes using 1,577 RP
samples.

Author Manuscript

MATERIALS AND METHODS
Prostate cancer (PCa) samples
A total of 1,577 patient PCa expression profiles (1,351 from FFPE tissue) were analyzed
from eight RP cohorts: Mayo Clinic (MCI & II) [9,21], Thomas Jefferson University (TJU)
[22], Cleveland Clinic (CCF)[23], Johns Hopkins (JHMI), Memorial Sloan Kettering
(MSKCC)[24], Erasmus MC (EMC)[25] and the German National Cancer Registry (DKFZ)
[26] (Table S1). In each of the eight RP cohorts, a single tumor focus per patient was
profiled (see Table S1 for selection criteria. The 1,351 FFPE samples were processed,
Eur Urol. Author manuscript; available in PMC 2016 October 01.
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assessed and analyzed using the Decipher clinical assay in the CLIA certified GenomeDx
Biosciences Laboratory (San Diego, CA). The remaining 226 samples from three cohorts
utilized RNA extracted in research laboratories from fresh-frozen or unfixed tissue
preserved in RNAlater. These samples were profiled in microarray core facilities of major
teaching hospitals and universities, although not to clinical grade standards. Data analysis
was performed as for the Decipher clinical assay.

Author Manuscript

For development of microarray-based classifiers, MCI was used as a discovery cohort where
407/580 patients had ERG status (by fluorescence in situ hybridization [FISH]) as
previously reported [27]; this cohort was split into training and validation sets of 252 and
155 patients, respectively, for training and validation of the microarray based ERG classifier
(m-ERG). The other cohorts without FISH or IHC ERG status (or assessment of non-ERG
ETS genes or SPINK1 expression) were used for classifier evaluation. See Appendix for
additional details.
Microarray data processing
RNA extraction and microarray expression data generation using the Affymetrix Human
Exon 1.0 ST arrays as part of the Decipher assay, including generation of the 22 gene
prognostic score, were described previously[9,21,24–26]. See Appendix for additional
details.
Development of ERG microarray-based classification models

Author Manuscript

We developed a Random Forrest (RF) supervised model (m-ERG) to predict FISH assessed
ERG rearrangement status using the MCI cohort, which has available FISH-ERG
information. The RF model was developed in a training subset of tumor patient profiles
(n=252) combined with 29 benign prostate tissue profiles (from the MSKCC cohort) prior to
assessment in the validation subset of MCI patient profiles (n=155) with known FISH-ERG
status. The m-ERG model generated scores ranging from 0 to 1, with higher scores
indicating increased likelihood of ERG rearrangement presence. Based on cut-off
optimization methods[28], a m-ERG score above 0.6 was used to define m-ERG+ profiles
from the training subset prior to application in the validation subset.
Development of ETV1, ETV4, ETV5, FLI1 and SPINK1 microarray-based classification
models

Author Manuscript

FISH and/or IHC was not available for the other non-ERG ETS family members or SPINK1
in cohorts assessed herein, precluding gold standard validation of classifiers for these
alterations. Hence, to develop classifiers, we performed unsupervised outlier analysis using
the ‘extremevalues’ R package on expression of core probesets (those in canonical exons)
for each gene using the entire MCI cohort (discovery) to define an expression threshold to
classify each sample as an outlier (or not) for each gene. This outlier detection method
estimates a model distribution for the discovery population (MCI) and using regression
analysis identifies outliers as observations that are unlikely to be drawn from the same
distribution. The minimum value of outliers in MCI was then set as the cutpoint to classify
samples from the evaluation cohorts as outliers. Patients with outlier profiles defined as just
described were annotated as m-ETV1+, m-ETV4+, m-ETV5+, m-FLI1+ or m-SPINK1+.
Eur Urol. Author manuscript; available in PMC 2016 October 01.
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In this study, we initially classified patient profiles into four previously reported subtypes
based on the results of the m-ERG, m-ETS and m-SPINK1 models. Tumor profiles with
high m-ERG score (m-ERG+) and m-ETV1−, m-ETV4−, m-ETV5−, m-FLI1− and mSPINK1− were classified as m-ERG+ subtype. Profiles that were m-ETV1+, m-ETV4+, mETV5+ or m-FLI1+ and m-ERG− were classified as m-ETS+ subtype, and those that were mSPINK1+ and m-ERG− were classified as m-SPINK1+ subtype. Finally, patient profiles that
are m-ERG−, m-ETV1−, m-ETV4−, m-ETV5−, m-FLI1− and m-SPINK1− were classified as
‘triple negative’. The four subtypes from this step were used to characterize the clinical and
molecular characteristics of each subtype. m-ERG+/m-ETS+ or m-ERG+/m-SPINK1+
profiles were considered as “conflict cases” and were assessed separately.
Statistical analysis

Author Manuscript

Statistical analyses were performed in R v3.0. All statistical tests were two-sided using
p<0.05 significance level. Univariable and multivariable logistic regression analysis were
performed to evaluate the statistical associations between microarray defined molecular
subtypes and clinical variables including age, race/ethnicity, pre-operative PSA, surgical
margin status (SMS), extraprostatic extension (EPE), seminal vesicle invasion (SVI), lymph
node involvement (LNI) and Gleason Score (GS). The multiple cohorts were considered as
random effect in the MVA regression model to remove individual cohort bias.

RESULTS
Clinical Characteristics of the Study Cohorts

Author Manuscript

To develop and validate computational tools for basic PCa molecular subtyping by gene
expression generated as part of the Decipher prognostic assay, we pooled RP samples from
1,577 patients from a total of 8 cohorts profiled using the Affymetrix Human Exon 1.0 ST
arrays (Table S1). These cohorts represent the spectrum of RP treated PCa from low to highrisk localized disease. Overall, 61% of patients in the pooled cohort had one or more adverse
pathology findings (APF: RP Gleason score ≥8, >pT2 or pN1); however, APF incidence of
ranged from 5%-89% between individual cohorts (Table S1). The majority of patients were
Caucasian (89%) and had aggressive PCa. Most of the patients received post-operative
hormonal and/or radiation therapy. Patients with metastasis had a median follow up time of
62 months (range, 3-213), and patients with no metastasis had a median follow up of 129
months [1-280]. Detailed clinicopathological information for the pooled cohort provided in
Table S2.

Author Manuscript

Microarray-based ERG (m-ERG) Model Development and Validation
The most informative microarray probesets for the m-ERG model were identified through a
multi-step procedure. First, in the training set (n=252), expression clustering of the 132 ERG
locus probesets demonstrated that most are highly correlated and informative of FISH-ERG
status (Figures 1A and S1A). Filtering of redundant and non-informative features (e.g., not
expressed above background) was performed prior to training a random forests (RF)
classifier for predicting FISH-ERG status. The final model used the expression values of 3
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ERG locus probesets and 2 probesets associated with FISH-ERG+ but low ERG expression;
AUC for predicting FISH-ERG status in the training set using the final m-ERG model was
0.98. In the validation subset (n=155 profiles, not used for training), the m-ERG model had
an AUC of 0.94 and an overall accuracy of 95% (Figure 1B). Most misclassified patients
had low ERG expression, consistent with previous reports that very small subsets of ERG
fusion-positive tumors (as detected by FISH) do not overexpress ERG protein [29].
Validation in benign tissue, cell line controls and technical replicates are reported in the
Appendix and Figure S1. When then applied to 1,170 patient profiles from the 7 cohorts not
used for training or testing, 550 (47%) were classified as m-ERG+ (38-64% across cohorts)
as shown in Figure 2.
Development of ETS and SPINK1 microarray classifiers

Author Manuscript

We next sought to classify patients based on SPINK1 over-expression, or outlier expression
of non-ERG ETS genes (ETV1, ETV4, ETV5 and FLI1) using over-expression as a surrogate
for rearrangement of the respective ETS gene. Heatmaps of all probesets from the ETV1,
ETV4, ETV5 and SPINK1 loci showed that a subset of patients over-expressed each gene, as
expected (Figure S2). Outlier analysis was first performed in the MCI cohort to define
outlier threshold cut-points for each gene (see Methods), which were then applied to the
remaining evaluation cohorts, as no gold standard data was available for profiled datasets
(Figure 1C). In MCI, microarray outlier analysis classified 5%, 1.7%, 0.5%, 1% and 7.7% as
m-ETV1+, m-ETV4+, m-ETV5+, m-FLI+ and m-SPINK1+, respectively (Table S3).
Performance of these classifiers in benign tissue, cell line controls and technical replicates
are reported in the Appendix.
Molecular subtyping of 1,577 RP patient specimens using the microarray-based classifiers

Author Manuscript
Author Manuscript

Across the 1,577 profiles from 8 cohorts, microarray analysis classified 46%, 8%, 1.1%,
1.6%, 0.6% and 8% as m-ERG+, m-ETV1+, m-ETV4+, m-ETV5+, m-FLI+ and m-SPINK1+,
respectively; 36% (n=575) lacked any outlier expression and were considered TripleNeg
(Table S3). Additionally, 3% of patient profiles had outlier expression for two or more
markers (m-ERG+/m-ETS+ or m-ERG+/m-SPINK1+ profiles), as shown in Table S3, which
we consider as conflict cases (see Discussion). To focus on cases with clearly defined
subtypes, we considered these conflict cases separately and collapsed the four ETS family
members into one group (given the low numbers of individual m-ETV1+, m-ETV4+, mETV5+ and m-FLI1+ profiles even in this large cohort). This analysis resulted in in four
molecular subtypes—m-ERG+, m-ETS+, m-SPINK1+ and TripleNeg— at 45%, 9%, 8% and
38% of samples, respectively (Figure 2), consistent with distributions in other predominantly
Caucasian cohorts assessed by for these individual subtypes by gene expression, FISH
and/or IHC[2,30].
Gene expression clustering of PCa molecular subtypes—The low frequency of
ETS+ and SPINK1+ subtypes has precluded comprehensive molecular and
clinicopathological evaluation in large cohorts to determine whether these minor PCa
subtypes represent distinct molecular subtypes, or are best classified as ERG+ and
TripleNeg, respectively. Hence, we first assessed whether m-ETS+ tumors (or m-SPINK1+
tumors) show global transcriptional profiles more similar to m-ERG+ or TripleNeg tumors.
Eur Urol. Author manuscript; available in PMC 2016 October 01.
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Thus, we first defined expression centroids for m-ERG+ and TripleNeg tumors using
transcriptome-wide differential expression analysis. To define m-ERG+ and TripleNeg
expression centroids, we selected all probesets with AUC>0.75 for discriminating for these
two subtypes (n=360 probesets). Calculating the distance between each m-ETS+ or mSPINK1+ sample and the m-ERG+ and TripleNeg subtypes centroids demonstrated that 98%
(117/119) of m-SPINK1+ tumors had cluster distances closer to the TripleNeg centroid. In
contrast, 35% of m-ETS+ tumors (48/139) had cluster distances closer to the m-ERG+
centroid, while 65% of m-ETS+ tumors were closer to the TripleNeg centroid (Figure 3A).
Defining m-ERG+ and TripleNeg expression centroids using other gene sets, as well as
fuzzy c-means clustering supported these results as described in Table S4, the Appendix,
and Figure S3. Together these analyses demonstrate that m-SPINK1+ tumors are highly
similar to TripleNeg tumors while m-ETS+ tumors are distinct from m-ERG+ tumors.

Author Manuscript

To gain additional insight into subtype relationships, the most predictive genes for each
subtype were defined based on AUC for discrimination of each subtype from the others.
Seventy six, 15, 14 and 3 genes had an AUC>0.7 for m-ERG+, m-ETS+, m-SPINK1+, and
TripleNeg, respectively (Table S5). Clustering expression of these discriminatory genes
across all samples demonstrated two main dendrogram branches corresponding to m-ERG+
and Triple Negative predictive genes. While m-ETS+ tumors shared expression of m-ERG+
predictive genes and expressed a unique subset of genes, the expression pattern of mSPINK1+ tumors was highly similar to TripleNeg PCa (Figure 3B). As expected, benign
samples clustered separately from all tumor samples. Subtype specific genes are described in
the Appendix.
Clinical associations of PCa molecular subtypes
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On univariable analysis, race, preoperative PSA, Gleason score (GS), extraprostatic
extension (EPE) and seminal vesicle invasion (SVI) status were non-uniformly distributed
across microarray defined subtypes (Table S6). We used multinomial multivariable analysis
to compare clinical and pathological characteristics between subtypes (Table 1). Compared
to TripleNeg, m-ERG+ PCa is associated with lower pre-operative PSA (OR=0.47, p<0.001)
and lower Gleason score (OR=0.43, p<0.001), but nearly twice as likely to have EPE
(OR=1.80, p<0.001) and nearly five times more likely to occur in Caucasian men (p<0.001)
(Table 1). The m-ETS+ subtype was more likely to have SVI compared to both TripleNeg
(OR=2.27, p=0.004) or m-ERG+ PCa (OR=1.96, p=0.01) (Table 1). Both TripleNeg and mSPINK1+ tumors had significantly higher preoperative PSA (OR=2.12, p<0.001 and
OR=1.73, p=0.05, respectively) and Gleason scores (OR=2.3, p<0.001 and OR=3.0,
p<0.001, respectively), and were more common in African American patients (OR=5.44,
p=0.002 and OR=16.87, p<0.001, respectively), compared to m-ERG+ tumors. Interestingly,
m-SPINK1+ is significantly associated with lack of SMS compared to m-ERG+ (OR=0.58,
p=0.006). Together, these clinicopathologic associations are consistent with our
transcriptome analysis demonstrating that m-SPINK1+ and TripleNeg are highly similar,
while m-ERG+ and m-ETS+ have distinct features.

Eur Urol. Author manuscript; available in PMC 2016 October 01.

Tomlins et al.

Page 8

Impact of molecular subtypes on prognosis

Author Manuscript
Author Manuscript

To evaluate the impact of molecular subtyping on prognosis, we assessed the ability of the
subtypes to predict patient outcomes such as biochemical recurrence (BCR), metastasis
(MET) and prostate cancer death (PCSM) after RP (Table S7). ROC analysis showed that
the subtypes do not discriminate well for these endpoints (AUC ~0.5). Likewise, across all
cohorts (excluding the MCI cohort used for development), Decipher [9] showed similar
discrimination (as measured by AUC) for metastasis in all four subtypes (Figure 4). Other
prognostic signatures such as CCP, GPS and the Penney et al. signature [10,31,32], which
can be derived from our global gene expression data, also showed similar discrimination for
metastasis in all subtypes except the microarray derived (md-)GPS signature, which was not
discriminative in the m-SPINK+ subtype (Figure S4). Lastly, Kaplan-Meier analyses in the
MCII cohort failed to show significant differences in time to events for BCR (Figure 5A)
and metastasis (Figure 5B) endpoints between the subtypes. However, a trend toward
significance was observed with the Triple Negative subtype patients having worse PCSM
than the other subtypes (Figure 5C). Together, these results support limited prognostic utility
for molecular subtypes in the post-RP setting where most patients receive post-operative
hormonal and/or radiation therapy.

DISCUSSION

Author Manuscript

High throughput technologies such as DNA microarrays and next generation sequencing
have greatly increased our understanding of PCa molecular alterations, including defining
molecular subtypes and the identification of prognostic gene expression signatures.
Although well validated antibodies and FISH/RISH assays have been developed for research
and clinical applications, comprehensive subtyping using these assays remains challenging
and has not been applied to large translational research cohorts. Likewise, the lack of current
clinical indications in PCa makes comprehensive molecular subtyping cost prohibitive in
routine clinical practice. This lack of large, comprehensively subtyped clinical cohorts has
hindered thorough evaluation of subtype specific clinicopathological associations and
molecular features. However, the development and uptake of clinically available, FFPE
compatible, gene expression based prognostic assays [8–11] suggests that expression
profiling data will be available for tens of thousands of patients in the immediate future.
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Hence, in this study, we sought to determine whether the “extra” gene expression data
generated as part of the clinically available Decipher assay, which derives a 22 gene
prognostic score from genome-wide microarray expression profiling, can be used to
determine molecular subtypes. Thus, we built computational models to predict the most
common PCa molecular subtypes defined by alterations resulting in marked transcript overexpression: ERG, ETV1, ETV4, ETV5 and FLI1(due to rearrangement) as well as SPINK1
(unknown mechanism). Our m-ERG classifier demonstrated 95% accuracy in predicting
FISH-ERG status in an independent validation set, similar to the reported accuracy of ERG
IHC [29,33,34] as used diagnostically in challenging cases [35]. In the pooled cohort, 45%
of patients were predicted as m-ERG+, similar to 47% ERG rearrangement positive
frequency reported from a meta-analysis of over 10,000 PCa samples [36]. We also
demonstrated the robustness of this m-ERG classifier using PCa/normal prostate tissue pairs

Eur Urol. Author manuscript; available in PMC 2016 October 01.
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and technical replicates. Hence, using this validated classifier, the Decipher prognostic assay
can also assess ERG status, without the cost or delay of separate IHC or FISH based
evaluation.
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We also developed microarray based classifiers for gene fusions involving other non-ERG
ETS genes (m-ETS), as well as SPINK1 over-expression (m-SPINK1). As gold standard
FISH/IHC data for assessing the performance of these classifiers was unavailable, findings
from these analyses should be considered exploratory, representing a limitation of our study.
We also identified a total of 3% of cases with m-ERG+/m-ETS+ or m-ERG+/m-SPINK1+
profiles. In our experience, ERG, non-ERG ETS and SPINK1 subtype defining alterations
are nearly always mutually exclusive, and observed co-occurrence is most likely due to
either misclassification (given the lack of gold standard training data for non-ERG
classifiers) or profiling of collisions between genetically distinct tumor clones (which may
appear morphologically indistinguishable), although exceptionally rare examples of focal
SPINK1 expression in otherwise ERG+ tumor have been reported[7,37,38]. As shown by
multivariate analysis (Table S8), conflict cases identified herein show similar
clinicopathological associations as m-ERG+ PCa, consistent with an enrichment of m-ERG+
tumors in these conflict cases Thus, studies are ongoing to generate gold standard data for
these non-ERG based classifiers. Importantly, however, for clinicopathological assessment
of our microarray defined subtypes, only cases with clearly defined single subtypes were
included, limiting the impact of these conflict cases on our findings.
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Our combined cohort was comprised of over 1,500 PCa patient profiles, allowing us to
explore clinicopathological and molecular correlates from these microarray defined subtypes
which have not been addressed in smaller or less comprehensive studies. By multivariable
analysis, m-ERG+ status was significantly associated with lower Gleason score, lower preoperative serum PSA, and European American race. These findings were in keeping with
other large RP cohorts [36] and further support the validity of our approach. Interestingly,
although m-ETS+ PCa was associated with lower PSA when compared to TripleNeg PCa,
this subtype was specifically associated with increased SVI when compared to both mERG+ and TripleNeg. On the other hand, m-SPINK1+ PCa was specifically associated with
Black/African American race, in line with recent findings from an IHC based RP study
assessing molecular subtypes and race [39].
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At the molecular level, we also attempted to address whether m-ETS+ and m-SPINK1+ PCa
are similar to m-ERG+ or TripleNeg tumors, respectively, or represent distinct subtypes.
Results revealed that most m-SPINK1+ PCa cluster with TripleNeg based on global and
supervised gene expression, unlike m-ETS+ PCa, which shared molecular overlap with both
TripleNeg and m-ERG+ subtypes. Clinicopathologic associations similarly demonstrate the
differences between m-ERG+ and other m-ETS+ PCa, as well as the similarity between mSPINK1+ and TripleNeg PCa. Thus we believe PCa can be grouped into three clinically and
molecularly distinct groups (m-ERG+, m-ETS+ and m-SPINK1+/TripleNeg), although the
detection of SPINK1 may still be useful as a single gene marker, particularly given the
frequency of over-expression in Black/African American patients (even compared to
TripleNeg).
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A limitation of our study is the lack of assessment of other relevant genomic lesions that
occur across (e.g. PTEN deletion) or within specific molecular subtypes (e.g. SPOP
mutations or CHD1 deletions/mutations in ERG− PCa). Efforts are ongoing to develop
classifiers for these events, however they are more challenging to detect in gene expression
data than outlier over-expression based events. Likewise, although our study suggests that
ERG+ and non-ERG ETS+ PCa subtypes should not be combined in clinicopathological
analyses, several thousand more samples will need to be profiled to inform on whether the
non-ERG ETS+ subtype should be stratified by individual alterations (e.g. ETV1+ vs.
ETV4+). Additional limitations include the lack of central histological review and the
inclusion of a small subset of fresh frozen samples (n=226) assessed outside the CLIA
laboratory. All cohorts derive from centers with expert genitourinary pathologists and we
have shown high concordance of Decipher profiles from matched fresh frozen and FFPE
samples assessed as herein ([40] and data not shown). Hence, although these factors may
limit our ability to observe associations, our results are likely more generalizable and several
individual clinicopathological associations observed herein (e.g. less frequent ERG+ in
African American men) are consistent with prior studies.

Author Manuscript

The recognition of over-treatment has led to an enormous interest in the development of
prognostic biomarkers, including several commercially available gene expression based
prognostic assays applicable to routine biopsy or RP specimens [9,10,31]. Whether such
assays are similarly prognostic across previously defined molecular subtypes had not been
assessed. Our results herein, which show limited effect of subtyping on prognosis and
prognostic assay performance, are consistent with large FISH/IHC based studies of ERG and
SPINK1 status in RP cohorts that show a lack of prognostic ability for predicting postsurgical outcomes. Why subtypes lack prognostic ability despite strong associations with
known prognostic pathological parameters (i.e. m-ETS+ associated with SVI), and the
reasons for potential conflicting prognostic associations (i.e. m-ERG+ associated with
Gleason score <7 and EPE), will require additional research. We and others have
hypothesized that subtype defining lesions may play a more important role in tumor
initiation and local growth characteristics, rather than in the factors that drive post-resection
recurrence[36,41], suggesting prognostic/predictive applications in non-RP based cohorts
(as discussed below).
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Despite the lack of impact on post-RP prognosis, we anticipate that incorporating molecular
subtyping into a clinically available prognostic assay has several areas of potential near term
clinical utility. For example, ERG status has been reported as prognostic in several non-RP
cohorts. Most notably, assessing a cohort of 217 active surveillance (AS) patients, Berg et
al. reported that patients with any ERG+ cores at diagnosis (by IHC) were more than twice
as likely to progress compared to ERG− patients; ERG+ was the most significant predictor of
AS progression in multivariable Cox regression analysis[42]. These findings are in keeping
with the hypothesis that ERG rearrangements may drive local growth as described above and
hence molecular subtyping may be particularly relevant in the AS setting. Although
Decipher has received Medicare coverage in the U.S. for post-RP prognosis, efforts to apply
this assay to diagnostic biopsy specimen are ongoing. Given the use of other prognostic
assays that assess biopsy specimens (such as Oncotype DX and Prolaris) largely in patients
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considering AS, application of Decipher in this setting will enable assessment of the impact
of m-ERG, m-ETS, mSPINK1/TripleNeg subtypes on prognosis in this setting without the
need for additional IHC/FISH/RISH based subtyping.
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Likewise, incorporating ERG status into prognostic tests may have utility in evaluating
multifocality/clonality. PCa is commonly multifocal, where a single prostate may harbor
multiple genetically distinct tumor foci (as has been demonstrated through ERG status) that
may be indistinguishable by routine histology. For example, patients on AS who have
consecutive biopsies with discordant microarray subtypes would indicate that different
tumor clones were sampled, as has been shown by IHC based ERG assessment in a patient
who developed an aggressive interval cancer while on active surveillance [20]. Of critical
importance, our approach can now be used to profile multiple foci at RP (or multiple
involved prostate biopsy cores) and directly assess the impact of true multifocality (as
indicated by discordant subtypes) on the Decipher prognostic score and other derived
prognostic signatures. Although other prognostic assays have reported robustness to
multifocality [10], molecular subtyping was not incorporating and hence it is unclear if
separate areas of the same tumor focus or truly genetically independent tumors (as would be
indicated by discordant subtypes) were profiled. Given the need for prognostic assays to be
reflective of the most aggressive tumor focus, even if not sampled in the assessed biopsy
specimen, our approach can be used to directly assess the robustness of prognostic assays to
true multifocality.
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Lastly, the ability to robustly detect molecular subtypes allows for pre-specified molecular
subgroup analyses or enrichment of patient populations for clinical trials [20], which
although common in precision medicine approaches in other cancers, are not routinely used
in PCa. Importantly, ETS rearrangements are nearly always early, clonal alterations,
suggesting that subtypes identified in diagnostic biopsy or RP samples will be maintained
through advanced disease [1–3]. As an example of the potential predictive utility of PCa
molecular subtypes, Galletti et al. demonstrated that in a pilot cohort of 34 men with
metastatic castration resistant PCa (CRPC) treated by docetaxel chemotherapy, men with
ERG+ primary tumors (by IHC) were nearly twice as likely to show resistance (by lack of
PSA response) than men with ERG− tumors [43]. Likewise, pre-clinical data supports
targeting of specific subtype defining alterations (e.g. targeting PARP in ERG+ or ETS+ and
targeting EGFR in SPINK1+ PCa)[44,45], culminating in ongoing clinical trials are ongoing
that require ERG and ETV1 status evaluation (NCT01576172). Importantly, several
molecularly defined subtypes in other cancers, (i.e. KRAS/ALK/EGFR mutant lung cancer)
show little to no association with prognosis but have distinct clincopathological features and
became predictive and clinically useful only after the development of targeted therapies
[46,47].

CONCLUSIONS
Several lines of evidence support PCa molecular subtypes, defined largely by mutually
exclusive genomic/transcriptomic events. The most commons subtype defining lesion—
ERG rearrangement—has been evaluated clinically by FISH and IHC. Herein, we validate
the use of extra data from a clinically available gene expression based prognostic assay
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(Decipher) for assessing ERG rearrangement status. Additionally, although
clinicopathological and molecular associations for m-ERG+ vs. m-ERG− PCa are well
described, little is known about less frequent subtypes. Hence, we also developed classifiers
for subtypes defined by rearrangements of other ETS genes or SPINK1 over-expression and
explored associations in over 1,500 PCa. Importantly, gene expression profiles and
clinicopathological associations support three general molecular subtypes (m-ERG+, mETS+, and m-SPINK1+/TripleNeg), providing the most comprehensive support for
distinguishing ERG+ and ETS+ PCa. Of note, although IHC/FISH/RISH assays have been
developed to assess these molecular subtypes, our microarray based classifiers are derived
from “extra” data generated as part of the Decipher assay, a prognostic assay performed in a
CLIA certified laboratory; hence a potential advantage of this assay compared to other
assays is the inclusion of molecular subtyping information without the need for additional
testing, delay or cost. Taken together, we demonstrate the validity of PCa molecular
subtyping using extra data from a gene expression based prognostic assay and identify novel
clinicopathological and molecular correlates to these subtypes. Although we demonstrate
that molecular subtypes are not prognostic in the post-prostatectomy setting (nor impact the
performance of currently available prognostic signatures), we anticipate that molecular
subtyping will complement purely prognostic based tests in several areas of PCa
management including non-RP cohorts.
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PATIENT SUMMARY
Prostate cancer molecular subtyping can be achieved using “extra” data generated from a
clinical-grade genome wide expression profiling prognostic assay (Decipher).
Transcriptomic and clinical analysis support three distinct molecular subtypes: 1) mERG+ 2) m-ETS+, and 3) m-SPINK1+/Triple Negative (m-ERG−/m-ETS−/m-SPINK1−).
Incorporation of subtyping into a clinically available assay may enable additional
applications beyond routine prognosis.
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Figure 1. Development and validation of microarray based prostate cancer (PCa) molecular
subtyping using genome wide expression profiling data from the Decipher assay
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A. Development of a microarray based ERG rearrangement classifier (m-ERG) from
genome wide expression profiling data from the Decipher assay. Unsupervised clustering of
the training subset (n=252 samples) from the discovery cohort (Mayo Clinic I) was
performed using gene expression from ERG exon (orange) and intron (green) probe sets (5′
on bottom). Expression of five summarized features was used to train a random forest (RF)
classifier based on known fluorescence in situ hybridization (FISH) assessment of ERG
rearrangement status (F-ERG) . m-ERG and F-ERG status for each profiled sample are
indicated in the header according to the legend. B. m-ERG scores in the validation subset
(n=155) of the discovery cohort are plotted with stratification by F-ERG status. The
predefined m-ERG+/ERG− score cutoff is indicated by the black dashed line. Classification
results are shown in the contingency table. C. Development of microarray based classifiers
for other ETS gene rearrangements and SPINK1 over-expression using outlier analysis.
Beeswarm plots show core-level expression of ETV1, ETV4, ETV5, FLI1 and SPINK1 in the
discovery (n=580 samples, left panels) and evaluation cohorts (n=997 samples, right panels).
Outlier analysis was used to define indicated cut-off scores for m-ETV1, m-ETV4, m-ETV5,
m-FLI1, and m-SPINK1 classifiers in the discovery cohort and then applied to the
evaluation cohort.
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Figure 2. Distribution of molecular PCa subtypes across assessed cohorts

In each cohort (total samples assessed given), the percentage of samples in each microarray
defined subypte (m-ERG+, m-ETS1+, m-SPINK1+ and m-ERG−/m-ETS−/m-SPINK1−
[TripleNeg]) are shown according to the legend. Cohorts are ordered based on frequency of
Adverse Pathology Findings (APF%, bottom panel). Mayo Clinic I (bolded) was used as the
discovery cohort, while the remaining cohorts were used as the evaluation cohort.
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Figure 3. Gene expression profiling support high similarity of m-SPINK1+ and TripleNeg
subtypes, unlike m-ETS+ and m-ERG+ PCa

A. m-ERG+ and TripleNeg expression centroids were generated by identifying all probesets
(n=360) with AUC>0.7 for discriminating m-ERG+ and TripleNeg samples across all
cohorts (n=1,531 samples). To assess the relationship of m-SPINK1+ and m-ETS+ PCa to
m-ERG+ and TripleNeg, the relative closeness of each m-SPINK1+ or m-ETS+ sample to
the m-ERG+/TripleNeg centroids is plotted (larger value indicates more similarity). B.
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Clustering of subtype defining gene expression demonstrates overlap of m-SPINK1+ and
TripleNeg PCa and unique profiles of m-ETS+ PCa. Expression of the most predictive genes
for each subtype (AUC>0.70 for discrimination from all other subtypes, n=360) were used
for clustering all profiled samples (n=1531). Benign specimens (yellow) from the DKFZ
cohort clustered separately from all PCa samples.
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Figure 4. Performance of a multigene PCa prognostic predictor (Decipher) is similar across
molecular subtypes
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The Decipher score (greater score predicts increased aggressiveness) for each profiled
sample in the pooled cohorts (n= 997, excluding Mayo Clinic I as it was used for Decipher
discovery) is plotted, stratified by assigned molecular subtypes. Patients who developed
metastasis or not are indicated by blue and red points, respectively, and median scores per
subtype are indicated by bars. The AUC for Decipher score prediction of metastasis
development in each subtype (along with 95% CI) is given. AUCs in each subtype were
significantly greater than expected by chance (p<0.0001 for all subtypes).
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Figure 5. Kaplan Meier analysis demonstrates similar PCa outcome measures across molecular
subtypes
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Kaplan Meier analysis was performed for all Mayo Clinic II cohort samples (case cohort,
n=235 samples) stratified by assigned molecular subtype for A) biochemical recurrence
(BCR), B) metastasis (MET) and C) prostate cancer specific mortality (PCSM) free
survival. Log Rank p values are given, along with the percentage of each subtype
experiencing each outcome.
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and m-ERG+ (lower panel) as the reference. OR = odds ratio; CI= confidence interval; Pre-OP PSA = pre-operative serum PSA (reference: <20ng/mL); Race (reference: Caucasian); EPE = extraprostatic
extension; SVI = seminal vesicle invasion; PathGS = pathologic Gleason score at prostatectomy (reference: Gleason score 7); SMS = surgical margin status; LNI = lymph node involvement.

Multinomial multivariable logistic regression analysis was performed for clinicopathological variables and molecular subtypes across all 1,531 profiled samples with reference to TripleNeg (upper panel)
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